Serum cholesterol in treatment-resistant depression

George I. Papakostas, Timothy Petersen, Shamsah B. Sonawalla, Wendelien Merens, Dan V. Iosifescu, Jonathan E. Alpert, Maurizio Fava, Andrew A. Nierenberg

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objective: Patients with major depressive disorder (MDD) may have significant differences in cholesterol levels compared with healthy controls. A previous study by our group reported that depressed patients with elevated cholesterol levels (≥200 mg/dl) were significantly more likely to be nonresponders to fluoxetine treatment than depressed patients with nonelevated cholesterol levels. However, very little is known regarding cholesterol in patients with treatment-resistant depression (TRD). The purpose of this study was to compare cholesterol levels at baseline between depressed patients with and without TRD and to test whether cholesterol levels at baseline can predict clinical response in patients with TRD treated with open-label nortriptyline (NT). Methods: Ninety-two patients with TRD entered a 6-week open trial of NT. Baseline cholesterol levels were randomly collected for 59 of these patients. Controlling for age and gender, we compared baseline cholesterol and triglyceride levels for 35 patients with TRD who did not respond to NT with 205 non-TRD patients who responded to an 8-week open trial of fluoxetine. Furthermore, with the use of logistic regression, we tested whether baseline cholesterol levels predicted clinical response to NT in the patients with TRD. Results: Patients with TRD had higher triglyceride levels at baseline compared with depressed patients without TRD. Cholesterol defined as a dichotomous variable being elevated if equal to or greater than 200 mg/dl, predicted poor response to a 6-week open trial of NT in patients with TRD. Conclusions: The results of this study confirm the relationship between hypercholesterolemia and poor outcome in the treatment of MDD for patients with TRD.

Original languageEnglish (US)
Pages (from-to)146-151
Number of pages6
JournalNeuropsychobiology
Volume47
Issue number3
DOIs
StatePublished - 2003
Externally publishedYes

Fingerprint

Treatment-Resistant Depressive Disorder
Cholesterol
Serum
Nortriptyline
Fluoxetine
Major Depressive Disorder
Hypercholesterolemia
Triglycerides

Keywords

  • Cholesterol
  • Nortriptyline
  • Treatment-resistant depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)
  • Psychology(all)

Cite this

Papakostas, G. I., Petersen, T., Sonawalla, S. B., Merens, W., Iosifescu, D. V., Alpert, J. E., ... Nierenberg, A. A. (2003). Serum cholesterol in treatment-resistant depression. Neuropsychobiology, 47(3), 146-151. https://doi.org/10.1159/000070584

Serum cholesterol in treatment-resistant depression. / Papakostas, George I.; Petersen, Timothy; Sonawalla, Shamsah B.; Merens, Wendelien; Iosifescu, Dan V.; Alpert, Jonathan E.; Fava, Maurizio; Nierenberg, Andrew A.

In: Neuropsychobiology, Vol. 47, No. 3, 2003, p. 146-151.

Research output: Contribution to journalArticle

Papakostas, GI, Petersen, T, Sonawalla, SB, Merens, W, Iosifescu, DV, Alpert, JE, Fava, M & Nierenberg, AA 2003, 'Serum cholesterol in treatment-resistant depression', Neuropsychobiology, vol. 47, no. 3, pp. 146-151. https://doi.org/10.1159/000070584
Papakostas GI, Petersen T, Sonawalla SB, Merens W, Iosifescu DV, Alpert JE et al. Serum cholesterol in treatment-resistant depression. Neuropsychobiology. 2003;47(3):146-151. https://doi.org/10.1159/000070584
Papakostas, George I. ; Petersen, Timothy ; Sonawalla, Shamsah B. ; Merens, Wendelien ; Iosifescu, Dan V. ; Alpert, Jonathan E. ; Fava, Maurizio ; Nierenberg, Andrew A. / Serum cholesterol in treatment-resistant depression. In: Neuropsychobiology. 2003 ; Vol. 47, No. 3. pp. 146-151.
@article{d3940fba606a4770a1e03ef6ad3e7a40,
title = "Serum cholesterol in treatment-resistant depression",
abstract = "Objective: Patients with major depressive disorder (MDD) may have significant differences in cholesterol levels compared with healthy controls. A previous study by our group reported that depressed patients with elevated cholesterol levels (≥200 mg/dl) were significantly more likely to be nonresponders to fluoxetine treatment than depressed patients with nonelevated cholesterol levels. However, very little is known regarding cholesterol in patients with treatment-resistant depression (TRD). The purpose of this study was to compare cholesterol levels at baseline between depressed patients with and without TRD and to test whether cholesterol levels at baseline can predict clinical response in patients with TRD treated with open-label nortriptyline (NT). Methods: Ninety-two patients with TRD entered a 6-week open trial of NT. Baseline cholesterol levels were randomly collected for 59 of these patients. Controlling for age and gender, we compared baseline cholesterol and triglyceride levels for 35 patients with TRD who did not respond to NT with 205 non-TRD patients who responded to an 8-week open trial of fluoxetine. Furthermore, with the use of logistic regression, we tested whether baseline cholesterol levels predicted clinical response to NT in the patients with TRD. Results: Patients with TRD had higher triglyceride levels at baseline compared with depressed patients without TRD. Cholesterol defined as a dichotomous variable being elevated if equal to or greater than 200 mg/dl, predicted poor response to a 6-week open trial of NT in patients with TRD. Conclusions: The results of this study confirm the relationship between hypercholesterolemia and poor outcome in the treatment of MDD for patients with TRD.",
keywords = "Cholesterol, Nortriptyline, Treatment-resistant depression",
author = "Papakostas, {George I.} and Timothy Petersen and Sonawalla, {Shamsah B.} and Wendelien Merens and Iosifescu, {Dan V.} and Alpert, {Jonathan E.} and Maurizio Fava and Nierenberg, {Andrew A.}",
year = "2003",
doi = "10.1159/000070584",
language = "English (US)",
volume = "47",
pages = "146--151",
journal = "Neuropsychobiology",
issn = "0302-282X",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Serum cholesterol in treatment-resistant depression

AU - Papakostas, George I.

AU - Petersen, Timothy

AU - Sonawalla, Shamsah B.

AU - Merens, Wendelien

AU - Iosifescu, Dan V.

AU - Alpert, Jonathan E.

AU - Fava, Maurizio

AU - Nierenberg, Andrew A.

PY - 2003

Y1 - 2003

N2 - Objective: Patients with major depressive disorder (MDD) may have significant differences in cholesterol levels compared with healthy controls. A previous study by our group reported that depressed patients with elevated cholesterol levels (≥200 mg/dl) were significantly more likely to be nonresponders to fluoxetine treatment than depressed patients with nonelevated cholesterol levels. However, very little is known regarding cholesterol in patients with treatment-resistant depression (TRD). The purpose of this study was to compare cholesterol levels at baseline between depressed patients with and without TRD and to test whether cholesterol levels at baseline can predict clinical response in patients with TRD treated with open-label nortriptyline (NT). Methods: Ninety-two patients with TRD entered a 6-week open trial of NT. Baseline cholesterol levels were randomly collected for 59 of these patients. Controlling for age and gender, we compared baseline cholesterol and triglyceride levels for 35 patients with TRD who did not respond to NT with 205 non-TRD patients who responded to an 8-week open trial of fluoxetine. Furthermore, with the use of logistic regression, we tested whether baseline cholesterol levels predicted clinical response to NT in the patients with TRD. Results: Patients with TRD had higher triglyceride levels at baseline compared with depressed patients without TRD. Cholesterol defined as a dichotomous variable being elevated if equal to or greater than 200 mg/dl, predicted poor response to a 6-week open trial of NT in patients with TRD. Conclusions: The results of this study confirm the relationship between hypercholesterolemia and poor outcome in the treatment of MDD for patients with TRD.

AB - Objective: Patients with major depressive disorder (MDD) may have significant differences in cholesterol levels compared with healthy controls. A previous study by our group reported that depressed patients with elevated cholesterol levels (≥200 mg/dl) were significantly more likely to be nonresponders to fluoxetine treatment than depressed patients with nonelevated cholesterol levels. However, very little is known regarding cholesterol in patients with treatment-resistant depression (TRD). The purpose of this study was to compare cholesterol levels at baseline between depressed patients with and without TRD and to test whether cholesterol levels at baseline can predict clinical response in patients with TRD treated with open-label nortriptyline (NT). Methods: Ninety-two patients with TRD entered a 6-week open trial of NT. Baseline cholesterol levels were randomly collected for 59 of these patients. Controlling for age and gender, we compared baseline cholesterol and triglyceride levels for 35 patients with TRD who did not respond to NT with 205 non-TRD patients who responded to an 8-week open trial of fluoxetine. Furthermore, with the use of logistic regression, we tested whether baseline cholesterol levels predicted clinical response to NT in the patients with TRD. Results: Patients with TRD had higher triglyceride levels at baseline compared with depressed patients without TRD. Cholesterol defined as a dichotomous variable being elevated if equal to or greater than 200 mg/dl, predicted poor response to a 6-week open trial of NT in patients with TRD. Conclusions: The results of this study confirm the relationship between hypercholesterolemia and poor outcome in the treatment of MDD for patients with TRD.

KW - Cholesterol

KW - Nortriptyline

KW - Treatment-resistant depression

UR - http://www.scopus.com/inward/record.url?scp=0038316678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038316678&partnerID=8YFLogxK

U2 - 10.1159/000070584

DO - 10.1159/000070584

M3 - Article

C2 - 12759558

AN - SCOPUS:0038316678

VL - 47

SP - 146

EP - 151

JO - Neuropsychobiology

JF - Neuropsychobiology

SN - 0302-282X

IS - 3

ER -